Higher irisin is associated with greater grip strength and muscle mass in community-dwelling Koreans and lower hip-fracture risk in postmenopausal women. Cognitive associations differ: higher levels accompany better preoperative cognitive scores but poorer scores in people with obstructive sleep apnea. Human exercise trials report increases in irisin or no clear effect.
200 findings in 126 papers from 2013 to 2026, 28 of them since April 2026
“Changes in irisin and BDNF showed positive associations with MoCA domains”
“Healthy older adults exhibit a short-term acute peak irisin response to exercise (~17 %) comparable to that previously observed in younger populations”
Human trialsingle-bout exercise sessionserumn = 32
European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity·
Exercise increases irisin in hot environment (WBGT 32 °C) (+39.3 pg/mL SEM 8 post-exercise and +48.9 pg/mL SEM 10 end-recovery, p ≤ 0.043).
“Post-exercise and end-recovery irisin was elevated above baseline in both groups in the hot (+39.3 pg/mL SEM 8 and + 48.9 pg/mL SEM 10, respectively; both p ≤ 0.043) but not the temperate condition.”
Human trialin hot environment (WBGT 32 °C)serummetabolic rate: 200 W/m2, 3 h3 h exercise + 60 min recoverymales
“As shown in, we also observed a significant increase in circulating levels of irisin after the intervention (before: 43.9 ± 11.0 ng/ml vs. after: 53.9 ± 13.4 ng/ml, P < 0.05, d = 0.82).”
Aerobic exercise showed no clear effect on irisin in humans (exercise groups compared with controls).
“No significant changes were observed in irisin concentrations or HDL-C levels (p > 0.05).”
Human trialexercise groups compared with controlstreadmill running50 min per session, four times per week, at 65% of target heart rateeight weeksfemalesn = 8
High-intensity interval training increases irisin in humans.
“Analysis of irisin concentration showed that 8-week HIIT contributed to changes in this parameter (main effect of time, p < 0.001 and interaction of time and term, p < 0.0001).”
Combined aerobic and resistance training increases irisin in humans.
“sarcopenia-associated factors, including irisin and 25(OH)D3, increased significantly in patients with T2DM complicated with sarcopenia following the intervention.”
Combined aerobic and resistance training increases irisin in men with type 2 diabetes; both aerobic-resistance and resistance-aerobic sequences (A-R = 2.93 μg.L−1 (95% CI = 1.45-4.42); R-A = 3.31 μg.L−1 (95% CI = 1.13-5.49)).
“CT acted as a therapeutic modality of training for T2DM patients by increasing their irisin and FST and decreasing their MSTN concentrations”
Human trialin men with type 2 diabetes; both aerobic-resistance and resistance-aerobic sequences12 weeksmalesn = 51
Heat showed no clear effect on irisin in humans (p > 0.66).
“Despite inducing physiological strain, 9 h of passive heat exposure did not alter circulating irisin or betatrophin concentrations in any group (p > 0.66).”
Heat increases irisin in humans (+93.9 pg/mL SEM 26 post-exercise, +70.5 pg/mL SEM 38 end-recovery, both p ≤ 0.014).
“serum irisin concentrations did not differ between groups under either condition but were elevated relative to the temperate condition during post-exercise and end-recovery in the heat (+93.9 pg/mL SEM 26 and + 70.5 pg/mL SEM 38 respectively; both p ≤ 0.014).”
Whey protein increases irisin in humans (r = 0.667).
“Post hoc pairwise comparisons revealed a significantly greater increase in irisin levels in the EX + P group than in the CR group (r = 0.667, p < 0.001).”
Anamorelin showed no clear effect on irisin in humans.
“Serum irisin levels did not differ in the 2 treatment groups at baseline, and 12-month changes in serum irisin levels did not differ significantly in the 2 groups.”
Anamorelin showed no clear effect on irisin in humans (osteosarcopenia) (12-month change = 0.50 ± 1.2 (SD) ng/mL in anamorelin group and -0.08 ± 2.3 ng/mL in placebo; P = .191).
“Treatment with anamorelin, compared with placebo, did not significantly alter irisin levels”
Human trialosteosarcopeniaserum100 mg/day12 monthsn = 26
Aframomum melegueta increases irisin in humans (healthy Korean adults with overweight; compared with placebo) (+40.1 ng/mL versus placebo; 95% CI +30.2 to +50.0; d = 1.67).
“serum irisin rose +42.6 vs. +2.5 ng/mL (+40.1 ng/mL; 95% CI +30.2 to +50.0; d = 1.67)”
Human trialhealthy Korean adults with overweight; compared with placebo6-paradol-standardized extractserum500 mg/day12 weeksn = 65
Irisin showed no clear effect on muscle function in humans (P-values 0.5523 and 0.1467).
“but no statistical correlation between irisin and muscle function (The P-values for gait speed and chair test time are 0.5523 and 0.1467, respectively).”
Type 2 diabetes is linked with lower irisin in humans (newly diagnosed type 2 diabetes mellitus vs. prediabetes) (median 140.4 vs. 230.7 ng/mL, p < 0.0001).
“Serum irisin was significantly lower in T2DM than in PreDM (median 140.4 vs. 230.7 ng/mL, p < 0.0001).”
Humansnewly diagnosed type 2 diabetes mellitus vs. prediabetes
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme·
Irisin is linked with a lower risk of sarcopenia in humans (OR 0.98, 95% CI 0.97-0.99).
“Increased levels of irisin (OR, 0.98, 95% CI, 0.97-0.99) and apelin (OR, 0.97, 95% CI, 0.95-0.99) were associated with a decreased risk of sarcopenia.”
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme·
Irisin is linked with a lower risk of sarcopenia in humans after adjusting for body mass index, sex, energy intake, and age (OR 0.39 (95% CI 0.19-0.92), P = 0.03).
“logistic regression analysis reported a low risk for sarcopenia (odds ratio, 0.39; 95% confidence interval, 0.19-0.92; P = 0.03) in high irisin median levels”
Humansafter adjusting for body mass index, sex, energy intake, and age
Irisin is associated with major adverse cardiovascular events in humans (Per 1 ng/mL increase in circulating irisin) (26% lower MACE risk per 1 ng/mL increase in irisin).
“each 1 ng/mL increase in irisin was associated with a 26% reduction in MACE risk.”
HumansPer 1 ng/mL increase in circulating irisinn = 220
Irisin is associated with major adverse cardiovascular events in patients with established coronary artery disease after PCI (0 vs 0.92 vs 0.57 per 1000 person-days, P < 0.01).
“the incidence of MACE was significantly lower in the first irisin tertile compared with the second and third (incidence rate 0 vs 0.92 (0.51-1.61) vs 0.57 (0.28-1.14) events per 1000 person-days; P < 0.01).”
Humansin patients with established coronary artery disease after PCIn = 103
“T0 irisin showed significant discriminative value for POCD, with a cutoff value of 302.840 ng/mL (Area Under the Curve [AUC]: 0.817; sensitivity: 0.757; specificity: 0.765).”
Irisin is associated with verbal memory test in Tai Chi group at 6 months (r = 0.715, p = 0.013).
“At six months only in TC group irisin levels significantly correlated with RALVT D score (r = 0.715, p = 0.013) while a trend was found in ACE-R total (r = 0.553, p = 0.078) and TMT A (r=-0.576, p = 0.064) controlled by age and education.”
Irisin is associated with endothelial progenitor cells in humans (r = 0.52).
“A significant correlation between the increase of circulating irisin levels and the increase in the number of EPCs was observed by the intervention (r = 0.52, P < 0.05).”
National Institute of Neurological Disorders and Stroke$2.5MNational Institute of Arthritis and Musculoskeletal and Skin Diseases$699KJapan Society for the Promotion of Science¥14.6M
Human studies associate higher irisin with greater grip strength and muscle mass, but sarcopenia associations point both ways, including higher three-year risk. Cognitive associations also differ, with better verbal memory in a Tai Chi trial but lower cognitive scores in patients with obstructive sleep apnea. Exercise trials report increases or no change in irisin.
Irisin correlates inversely with Montreal Cognitive Assessment scores and distinguishes concurrent mild cognitive impairment in people with obstructive sleep apnea. Human trials associate irisin with cognitive improvement during exercise in women with fibromyalgia and show increased irisin after resistance training in postmenopausal women with MASLD.
Body fat fell by 4.2 percentage points with the extract versus 0.8 with placebo in a 12-week randomized trial.Body fat fell by 4.2 percentage points with the extract versus 0.8 with placebo in a 12-week randomized trial.